With a height of 36.5 meters and a floor area of some 4,700 square meters, the new building will not only create 300 jobs in Ulm, but also produce complex biotechnological active ingredients. As the global market leader in generics, this investment reflects Teva’s increasing focus on the field of biotechnological pharmaceuticals.

Drees & Sommer supported the company in its goal of speeding up the project.

The experts started by undertaking a 360-degree analysis and then took over overall construction management during the course of the project.

Although the EPCM contractor was in charge of construction, the Drees & Sommer team contributed significantly to reducing the customer’s workload in the area of managing the construction processes as well as coordinating the entire TEVA team during the execution phase.